Introduction {#s1}
============

Influenza A pandemic H1N1 2009 virus infections began to spread in Spain during spring 2009. Reports suggested high mortality in children and adults associated with the new virus in Mexico^[@DKS098C1],[@DKS098C2]^ and Argentina,^[@DKS098C3]^ as well as in previously healthy young people. Analysis of cases hospitalized in the USA showed a mortality rate of 7%, with 25% of patients being admitted to the intensive care unit (ICU).^[@DKS098C4]^ A study of 32 patients infected with the pandemic virus strain admitted to Spanish ICUs found a mortality rate of 25%, somewhat lower than in Latin American countries.^[@DKS098C5]^ These findings suggest that the H1N1 virus is more virulent than previous strains.

As there was no specific targeted vaccine giving protection against the H1N1 influenza virus available at the beginning of the outbreak, health authorities began to recommend administration of neuraminidase inhibitors to reduce transmission and/or complications. Various studies have suggested that these drugs are also effective in reducing the severity of the infection.^[@DKS098C4],[@DKS098C6],[@DKS098C7]^

We reviewed nationwide Spanish data on hospitalized patients with 2009 H1N1 influenza A in order to: (i) evaluate the frequency of adverse outcomes during hospitalization; and (ii) identify the factors influencing poor/good outcome, including the use of neuraminidase inhibitors shortly after the onset of symptoms.

Methods {#s2}
=======

Study design {#s2a}
------------

We carried out a multicentre study in 36 hospitals from seven Spanish regions (Andalusia, Catalonia, Castile and Leon, Madrid, Navarre, the Basque Country and Valencia). Between July 2009 and February 2010 we selected hospitalized patients with influenza syndrome, acute respiratory infection, septic shock or multiple organ failure in whom influenza virus A (H1N1) 2009 infection was confirmed by real-time reverse-transcription PCR (RT-PCR) from nasopharyngeal swabs; haemagglutinin (HA) sequencing was performed. We excluded patients who had nosocomial infection, defined as pandemic virus infection in a patient that appears ≥48 h after admission for another cause. All information collected was treated as confidential, in strict observance of legislation for observational studies. The study was approved by the Ethics Committees of the hospitals involved, following the Declaration of Helsinki principles. Written informed consent was obtained from all patients included in the study.

Selection of patients {#s2b}
---------------------

During the pandemic flu all patients suspected of having the disease, either in outpatient clinics or hospitals, were diagnosed by RT-PCR of samples from nasopharyngeal swabs. Within the next 48 h, hospitalized patients were interviewed at the centre. Of these, 23 rejected participation and 12 were excluded because flu had been acquired after hospital admission.

Data collection {#s2c}
---------------

The following demographic variables and pre-existing medical conditions were recorded for all study participants: age, sex, ethnicity, educational level, smoking, alcoholism, pregnancy in women aged 15--49 years, history of pneumonia in the previous two years, chronic obstructive pulmonary disease (COPD), asthma, cardiovascular disease, renal failure, diabetes, HIV infection, disabling neurological disease, cancer, transplantation, morbid obesity (body mass index ≥40), use of neuraminidase inhibitors before hospital admission (and their timing relative to the onset of symptoms, verified after contacting the prescribing general practitioner), use of other medications in the 90 days before hospital admission (corticosteroids, antibiotics etc.) and treatment received during hospitalization (medications, catheters and mechanical ventilation). For each vaccine, a case was considered vaccinated if the vaccine had been received ≥14 days before the onset of symptoms. Data were collected during hospital admission and the clinical chart was also reviewed after discharge.

The outcome variables were admission to an ICU, in-hospital death and length of hospital stay (in days). Given that the number of deaths was very low, a combined endpoint was classified as 'poor outcome': ICU admission and/or in-hospital death.

Statistical analysis {#s2d}
--------------------

Bivariate comparisons were made using Pearson\'s χ^2^ test for categorical variables and Student\'s *t*-test for continuous variables. As a measure of association, the relative risk (OR) and 95% CI were calculated. Logistic regression was applied in the multivariate analysis for dichotomous adverse outcomes. To determine the variables to be included in the multivariate analysis, the procedure described by Sun *et al*.^[@DKS098C8]^ was followed. Intermediate variables were discarded. We ran two stepwise models, one backward and another forward, including variables with *P *\< 0.2.^[@DKS098C9],[@DKS098C10]^ We constructed a list of predictors of mortality identified in other studies. Using information from stepwise models and the list of predictors, a saturated model was built, and by using a heuristic approach, variables that did not change the coefficient of the bundles by more than 10% were discarded, in order to construct a parsimonious model retaining all important confounders.

To analyse the impact of different variables on the length of hospital stay, patients who died were excluded from these analyses. Given that hospital stay did not follow the normal curve, natural logarithms were used. Firstly, to select potential variables related to length of stay, we used Cox regression in the same fashion as described above for the logistic regression analysis. The variables selected by this model were tested by including other potential candidates according to the logistic regression analyses. Secondly, an analysis of covariance was applied to estimate the adjusted means of hospital length of stay. All analyses were made using the Stata 10/SE package (College Station, TX, USA).

Results {#s3}
=======

There were a total of 813 patients \[410 (50.4%) were female, of which 51 (12%) were pregnant\]. The mean age was 38.5 years (SD 22.8) and 24% were aged \<18 years. The use of neuraminidase inhibitors was reported by 495 patients (60.9%), with oseltamivir being administered in all cases but two (zanamivir). During hospitalization, 79 patients (9.7%) were admitted to the ICU and 10 died (1.2%), of whom 9 were not receiving intensive care. No death occurred in pregnant women, of whom only one was admitted to the ICU. The timings of the use of neuraminidase inhibitors before hospital admission were: 332 patients in the first 24 h after the onset of symptoms, 97 between 24--48 h and 66 after 48 h (Table [1](#DKS098TB1){ref-type="table"}).

###### 

Description of the study population (*N *= 813)

  Variable                                                    
  ----------------------------------------------------------- ---------------
  Sex (female), *n* (%)                                       410 (50.4)
   pregnant, *n* (%)                                          51 (12.4)
  Age                                                         
   mean (SD)                                                  38.5 (22.8)
   median, IQR                                                41 (19--55)
   ≤18 years, *n* (%)                                         195 (24.0)
   19--45, *n* (%)                                            275 (33.8)
   46--65, *n* (%)                                            242 (29.8)
   \>65, *n* (%)                                              101 (12.4)
  Race (Caucasian), *n* (%)                                   708 (87.1)
  Vaccinated with pandemic H1N1 vaccine, *n* (%)              13 (1.6)
  Vaccinated with seasonal influenza vaccine, *n* (%)         155 (19.1)
  Smoking, *n* (%)                                            
   current                                                    178 (21.9)
   ex-smoker                                                  128 (15.7)
  Alcoholism, *n* (%)                                         44 (5.4)
  Corticosteroid therapy, *n* (%)                             31 (3.8)
  COPD, *n* (%)                                               76 (9.4)
  Number of comorbidities, n (%)                              
   0                                                          242 (29.8)
   1                                                          195 (24.0)
   2--3                                                       212 (26.1)
   ≥4                                                         164 (20.2)
  Use of neuraminidase inhibitors before admission, *n* (%)   495 (60.9)
  Admission to ICU, *n* (%)                                   79 (9.7)
  In-hospital death, *n* (%)                                  10 (1.2)
  Length of hospital stay (days), mean (median, IQR)          8.5 (5, 3--9)

The relationship between study variables and ICU admission/in-hospital death is shown in Table [2](#DKS098TB2){ref-type="table"}. In the univariate analyses, age, most comorbidities (COPD, diabetes, liver failure and cardiovascular disease), ex-smoking, corticosteroid therapy and histamine-2 receptor antagonists were associated with an adverse outcome during hospitalization. In the multivariate models, the variables significantly associated with a poor outcome were diabetes (OR = 2.21, 95% CI = 1.21--4.02), corticosteroid therapy (OR = 3.37, 95% CI = 1.39--8.20) and use of histamine-2 receptor antagonists (OR = 2.68, 95% CI = 1.14--6.36). Use of neuraminidase inhibitors was protective (OR = 0.57, 95% CI = 0.34--0.94). Pneumonia at admission, COPD, ex-smoking and liver failure showed a trend to association. The trend analysis for age in the multivariable analysis yielded a *P* value of 0.11, with advanced age associated with a higher risk of adverse outcome. When the timing of treatment with neuraminidase inhibitors after the onset of influenza was analysed, the benefit was confined to administration within the first 48 h after the onset of symptoms.

###### 

Association between study variables and ICU admission/in-hospital death, n

  Variable                                          Total   *n* (%)     OR (95% CI)         OR^a^ (95% CI)
  ------------------------------------------------- ------- ----------- ------------------- -------------------
  Sex                                                                                       
   female                                           410     40 (9.8)    0.80 (0.50--1.28)   0.87 (0.54--1.40)
   male                                             403     48 (11.9)   1 (ref.)            1 (ref.)
  Age (years)                                                                               
   ≤18                                              195     13 (6.7)    1 (ref.)            1 (ref.)
   19--45                                           275     27 (9.8)    1.52 (0.73--3.31)   1.33 (0.63--2.80)
   46--65                                           242     33 (13.6)   2.21 (1.09--4.71)   1.56 (0.73--3.33)
   ≥66                                              101     15 (14.9)   2.44 (1.03--5.83)   1.86 (0.76--4.55)
  Ethnicity                                                                                 
   Caucasian                                        708     82 (11.6)   0.46 (0.16--1.09)   0.56 (0.23--1.34)
   other                                            105     6 (5.7)     1 (ref.)            1 (ref.)
  Use of neuraminidase inhibitors                                                           
   yes                                              495     49 (9.9)    0.79 (0.49--1.26)   0.57 (0.34--0.94)
   ≤48 h within onset of symptoms                   429     36 (8.4)    0.66 (0.39--1.09)   0.46 (0.27--0.80)
   \>48 h                                           66      13 (19.7)   1.75 (0.80--3.63)   1.29 (0.61--2.70)
   no                                               318     39 (12.3)   1 (ref.)            1 (ref.)
  Vaccinated with pandemic H1N1 vaccine                                                     
   yes                                              13      2 (15.4)    1.51 (0.16--7.08)   1.65 (0.33--8.23)
   no                                               800     86 (10.8)   1 (ref.)            1 (ref.)
  Vaccinated with seasonal influenza vaccine                                                
   yes                                              155     15 (9.7)    0.86 (0.44--1.57)   0.60 (0.31--1.15)
   no                                               658     73 (11.1)   1 (ref.)            1 (ref.)
  Smoking                                                                                   
   ex-smoker                                        128     21 (16.4)   1.97 (1.07--3.52)   1.72 (0.94--3.13)
   current                                          178     21 (11.8)   1.34 (0.74--2.37)   1.22 (0.68--2.18)
   never                                            507     46 (9.1)    1 (ref.)            1 (ref.)
  Alcoholism                                                                                
   yes                                              44      8 (18.2)    1.91 (0.74--4.37)   1.46 (0.62--3.45)
   no                                               769     80 (10.4)   1 (ref.)            1 (ref.)
  COPD                                                                                      
   yes                                              76      14 (18.4)   2.02 (1.00--3.87)   1.76 (0.86--3.57)
   no                                               663     74 (10.0)   1 (ref.)            1 (ref.)
  Cardiovascular disease                                                                    
   yes                                              70      13 (18.6)   2.03 (0.97--3.97)   1.56 (0.76--3.16)
   no                                               7438    75 (10.1)   1 (ref.)            1 (ref.)
  Diabetes                                                                                  
   yes                                              98      19 (19.4)   2.25 (1.21--4.02)   2.21 (1.21--4.02)
   no                                               715     69 (9.7)    1 (ref.)            1 (ref.)
  Liver failure                                                                             
   yes                                              27      8 (22.9)    2.59 (0.98--6.09)   2.23 (0.93--5.34)
   no                                               778     80 (10.3)   1 (ref.)            1 (ref.)
  Corticosteroid therapy                                                                    
   yes                                              31      8 (25.8)    3.05 (1.14--7.35)   3.37 (1.39--8.20)
   no                                               782     80 (10.2)   1 (ref.)            1 (ref.)
  Treatment with histamine-2 receptor antagonists                                           
   yes                                              33      8 (24.2)    2.08 (1.05--6.66)   2.68 (1.14--6.36)
   no                                               780     80 (10.3)   1 (ref.)            1 (ref.)
  Pneumonia at admission                                                                    
   yes                                              178     26 (12.8)   1.29 (0.76--2.14)   1.69 (0.98--2.93)
   no                                               609     62 (10.2)   1 (ref.)            1 (ref.)
  No. of comorbidities                                                                      
   0                                                242     15 (6.2)    1 (ref.)            1^b^ (ref.)
   1                                                195     19 (9.7)    1.63 (0.76--3.56)   1.79 (0.88--3.65)
   2--3                                             212     27 (12.7)   2.21 (1.09--4.60)   2.57 (1.31--5.03)
   ≥4                                               164     27 (16.5)   2.98 (1.47--6.24)   3.86 (1.91--7.79)

^a^Adjusted by age, sex, antiviral treatment before admission, pneumonia at admission, liver failure, diabetes, cardiovascular disease, treatment with histamine-2 receptor antagonists, corticosteroids, smoking and alcoholism.

^b^Adjusted by age, sex, antiviral treatment before admission and pneumonia at admission.

Table [3](#DKS098TB3){ref-type="table"} shows the variables associated with length of hospital stay. The use of neuraminidase inhibitors within the first 2 days after the onset of influenza reduced hospital stay by a mean of 1.9 days (from 6.6 to 4.7, *P *\< 0.001), whereas delayed administration was associated with an increase in hospital stay. Pneumonia diagnosed at admission was clearly associated with longer hospital stay, as were comorbidities (COPD, neurological impairment and cardiovascular disease) and some therapies (proton pump inhibitors).

###### 

Length of hospital stay (LOS) in days and association with study variables

  Variable                           Crude LOS         Adjusted LOS                     
  ---------------------------------- ----------------- -------------- ----------------- ---------
  Use of neuraminidase inhibitors                                                       
   yes                                                                                  
    ≤48 h within onset of symptoms   4.9 (4.5--5.3)    0.001          4.7 (4.0--5.4)    \<0.001
    \>48 h                           9.4 (7.6--11.6)   0.001          8.8 (7.7--9.9)    0.014
   no                                6.3 (5.7--7.0)                   6.6 (6.0--7.3)    
  COPD                                                                                  
   yes                               7.6 (6.2--9.2)    0.003          7.4 (5.9--9.1)    0.012
   no                                5.5 (5.2--5.9)                   5.5 (5.2--5.9)    
  Antibiotics before admission                                                          
   yes                               6.1 (5.4--6.9)    0.196          6.2 (5.5--7.0)    0.073
   no                                5.5 (5.2--6.0)                   5.5 (5.1--5.9)    
  Corticosteroids before admission                                                      
   yes                               5.6 (4.9--6.4)    0.861          5.8 (5.4--6.2)    0.056
   no                                5.7 (5.3--6.1)                   5.1 (4.5--5.9)    
  Proton pump inhibitors                                                                
   yes                               7.4 (6.3--8.6)    0.001          6.6 (5.6--7.8)    0.032
   no                                5.4 (5.1--5.8)                   5.5 (5.1--5.9)    
  Pneumonia at admission                                                                
   yes                               6.1 (5.4--6.9)    0.148          6.7 (5.9--7.6)    0.004
   no                                5.5 (5.2--5.9)                   5.4 (5.0--5.8)    
  Neurological impairment                                                               
   yes                               7.8 (5.8--10.6)   0.034          8.5 (6.3--11.5)   0.006
   no                                5.6 (5.3--6.0)                   5.6 (5.2--5.9)    
  Ex-smoker                                                                             
   yes                               6.8 (5.8--7.8)    0.016          6.4 (5.5--7.4)    0.118
   no                                5.5 (5.1--5.9)                   5.6 (5.2--5.9)    
  Cardiovascular disease                                                                
   yes                               8.5 (7.0--10.4)   0.001          7.6 (6.2--9.3)    0.005
   no                                5.5 (5.1--5.8)                   5.5 (5.2--5.9)    

Discussion {#s4}
==========

We found that traditional risk factors associated with hospitalization in patients with influenza (COPD and corticosteroid therapy before admission) were also found in our patients. Likewise, the use of neuraminidase inhibitors reduced the probability of adverse outcomes during hospital stay and significantly shortened the length of stay.

This study is observational and can be affected by several limitations. Kumar^[@DKS098C11]^ has recently highlighted the drawbacks of observational studies in estimating the benefits of early viral treatment in the prognosis of flu. We agree that selection bias is difficult to avoid. Immortal time bias or survival-duration-related selection bias imply that the late use of antivirals may be related to a better prognosis, whereas in fact our results suggest the opposite.

Our results show no benefit of late neuraminidase treatment. In Israel, a retrospective cohort study documented a higher rate of complications after admission.^[@DKS098C12]^ Severe complications (excluding hypoxia and uncomplicated pneumonia) occurred more frequently with late oseltamivir. In the same way, a Spanish study of ICU patients showed that ICU length of stay, days of mechanical ventilation and mortality were reduced in patients receiving early treatment versus late treatment with oseltamivir.^[@DKS098C13]^ These reports do not give comparisons with flu patients without antiviral treatment.

The mortality rate in our study (1.2%) was low in comparison with other studies. This may be due to the fact that our patients were not all admitted to the ICU,^[@DKS098C5],[@DKS098C14]^ and did not all have pneumonia at hospital admission.^[@DKS098C15]^ Even so, the mortality rate was clearly lower than that found in the USA at the beginning of the pandemic (7%)^[@DKS098C4]^ or the 4.9% reported in Canada.^[@DKS098C16]^

Likewise, the rate of ICU admission (9.7%) was lower than that found in the USA (25%)^[@DKS098C4]^ and Canada (16%),^[@DKS098C16]^ although it was similar to the 8% reported in New Zealand Maoris.^[@DKS098C17]^ Some form of selection bias cannot be completely ruled out as our study patients had to be interviewed to collect data on the use of medications before admission and other risk factors related to disease severity. In a study carried out in Catalonia (north-east Spain), of 773 cases hospitalized, 37.9% were admitted to the ICU.^[@DKS098C18]^ In contrast, in Andalusia (southern Spain), 28 out of 311 hospitalized cases (9%) were admitted to an ICU.^[@DKS098C19]^ In another Spanish study of patients admitted to the ICU, the mortality rate was 22%.^[@DKS098C20]^ Taken together, these data suggest that patients who died shortly after admission were not picked up by our study.

The predisposing factors for a higher probability of adverse outcome during hospitalization were broadly similar to those found in other studies.^[@DKS098C16],[@DKS098C21]^ In one international series of patients with community-acquired pneumonia, male sex and obesity were predictors of mortality, although we did not find similar results.^[@DKS098C15]^

We found a significant association between reductions in ICU admission/death and the administration of neuraminidase inhibitors within the first 48 h after the onset of symptoms, similarly to the findings of Jain *et al*.^[@DKS098C4]^ and other studies.^[@DKS098C6],[@DKS098C7]^ In these reports none of the pregnant women who died had taken neuraminidase inhibitors within the first two days after the onset of illness.

Early use of neuraminidase inhibitors was associated with shorter hospital stay. Other reports have found no relationship between antiviral treatment and hospital stay.^[@DKS098C22]^

In summary, we found that early treatment with neuraminidase inhibitors had a beneficial effect on outcomes during hospitalization and on the length of hospital stay in patients with HIN1 virus infection.
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